Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort.

Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study

Bettiol, Alessandra;Baldini, Chiara;Cinetto, Francesco;Vacca, Angelo;Padoan, Roberto;
2021

Abstract

Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort.
2021
File in questo prodotto:
File Dimensione Formato  
cinetto MEPOLIZUMAB.pdf

accesso aperto

Tipologia: Published (Publisher's Version of Record)
Licenza: Creative commons
Dimensione 722.91 kB
Formato Adobe PDF
722.91 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11577/3400497
Citazioni
  • ???jsp.display-item.citation.pmc??? 41
  • Scopus 100
  • ???jsp.display-item.citation.isi??? 104
  • OpenAlex ND
social impact